Nwosu Zeribe Chike, Megger Dominik Andre, Hammad Seddik, Sitek Barbara, Roessler Stephanie, Ebert Matthias Philip, Meyer Christoph, Dooley Steven
Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Molecular Hepatology Section, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Cell Mol Gastroenterol Hepatol. 2017 May 31;4(2):303-323.e1. doi: 10.1016/j.jcmgh.2017.05.004. eCollection 2017 Sep.
BACKGROUND & AIMS: Cancer cells rely on metabolic alterations to enhance proliferation and survival. Metabolic gene alterations that repeatedly occur in liver cancer are largely unknown. We aimed to identify metabolic genes that are consistently deregulated, and are of potential clinical significance in human hepatocellular carcinoma (HCC).
We studied the expression of 2,761 metabolic genes in 8 microarray datasets comprising 521 human HCC tissues. Genes exclusively up-regulated or down-regulated in 6 or more datasets were defined as consistently deregulated. The consistent genes that correlated with tumor progression markers ( and (Pearson correlation .05) were used for Kaplan-Meier overall survival analysis in a patient cohort. We further compared proteomic expression of metabolic genes in 19 tumors vs adjacent normal liver tissues.
We identified 634 consistent metabolic genes, ∼60% of which are not yet described in HCC. The down-regulated genes (n = 350) are mostly involved in physiologic hepatocyte metabolic functions (eg, xenobiotic, fatty acid, and amino acid metabolism). In contrast, among consistently up-regulated metabolic genes (n = 284) are those involved in glycolysis, pentose phosphate pathway, nucleotide biosynthesis, tricarboxylic acid cycle, oxidative phosphorylation, proton transport, membrane lipid, and glycan metabolism. Several metabolic genes (n = 434) correlated with progression markers, and of these, 201 predicted overall survival outcome in the patient cohort analyzed. Over 90% of the metabolic targets significantly altered at the protein level were similarly up- or down-regulated as in genomic profile.
We provide the first exposition of the consistently altered metabolic genes in HCC and show that these genes are potentially relevant targets for onward studies in preclinical and clinical contexts.
癌细胞依靠代谢改变来增强增殖和存活能力。肝癌中反复出现的代谢基因改变在很大程度上尚不明确。我们旨在识别在人类肝细胞癌(HCC)中持续失调且具有潜在临床意义的代谢基因。
我们研究了8个包含521个人类HCC组织的微阵列数据集中2761个代谢基因的表达。在6个或更多数据集中仅上调或下调的基因被定义为持续失调。将与肿瘤进展标志物相关(Pearson相关系数>0.05)的一致性基因用于患者队列的Kaplan-Meier总生存分析。我们进一步比较了19个肿瘤与相邻正常肝组织中代谢基因的蛋白质组表达。
我们识别出634个一致性代谢基因,其中约60%在HCC中尚未被描述。下调基因(n = 350)大多参与生理性肝细胞代谢功能(如异生物质、脂肪酸和氨基酸代谢)。相比之下,在持续上调的代谢基因(n = 284)中,有参与糖酵解、磷酸戊糖途径、核苷酸生物合成、三羧酸循环、氧化磷酸化、质子转运、膜脂和聚糖代谢的基因。几个代谢基因(n = 434)与进展标志物相关,其中201个在分析的患者队列中预测了总生存结果。在蛋白质水平上显著改变的代谢靶点中,超过90%在基因组图谱中同样上调或下调。
我们首次阐述了HCC中持续改变的代谢基因,并表明这些基因可能是临床前和临床研究的潜在相关靶点。